Chemotherapy May Cause Nerve Damage In Some Child Cancer Patients: Study

|

Children who undergo chemotherapy for treatment of cancer may face an increased risk of developing peripheral neuropathy as an adult, according to the findings of a new study. 

Researchers from the Sydney Children’s Hospital indicate that more than 50% of patients who had chemotherapy as children were diagnosed with peripheral neuropathy later in life. The findings were published May 14, in the medical journal JAMA Neurology.

Peripheral neuropathy occurs when there is damage to the nerves in the body. It often causes weakness, numbness, tingling, burning, and pain in the hands and feet. It may result in reduced movement, clumsiness, sensitivity to light and temperature.

Sports-Betting-Addiction-Lawsuits
Sports-Betting-Addiction-Lawsuits

The study examined data for 121 childhood cancer survivors treated with chemotherapy for extra cranial malignancy before the age of 17. Cancer patients were compared with healthy age matched control subjects.

Patients were compared for the different types of neurotoxic chemotherapy agent used as well as incidence of neuropathy among patients.

Overall, neuropathy was seen in 50% of patients treated with chemotherapy. Researchers also noted chemo treatment was associated with lower limb predominant sensory axonal neuropathy.

The most common neurotoxic agents used on patients were vinca alkaloids, given to about 71% of patients, and platinum compounds, given to 16% of patients. Roughly 10% of patients were given a combination of both platinum and vinca alkaloids.

Long-term neurotoxicity occurred more often among patients treated with cisplatin than with vinca alkaloids, carboplatin without cisplatin, or than among patients treated with no neurotoxic agents. Neuropathy occurred in 85% of patients given cisplatin, compared to 29% of patients given vinca alkaloids.

Researchers noted patients also experienced functional deficits in manual dexterity, distal sensation, and balance. They also experienced a reduction in the quality of life and physical functioning.

Chemotherapy-induced neuropathy in children is often considered something that may happen during treatment, but is not a long-term concern. However, the findings of the study show this can be a long term problem for those who were treated with neurotoxic agents.

Written by: Martha Garcia

Health & Medical Research Writer

Martha Garcia is a health and medical research writer at AboutLawsuits.com with over 15 years of experience covering peer-reviewed studies and emerging public health risks. She previously led content strategy at The Blogsmith and contributes original reporting on drug safety, medical research, and health trends impacting consumers.

Image Credit: |



2 Comments


Mark
I had cisplatin and decadin and compazine and allopurinal and vinblastine media and inflatable now I have nerve damage burning and tingling in feet and legs I done it 11years ago still affects me

Mark
I had cisplatin and decadin and compazine and allopurinal and vinblastine media and inflatable now I have nerve damage burning and tingling in feet and legs I done it 11years ago still affects me

This field is for validation purposes and should be left unchanged.

Share Your Comments

This field is hidden when viewing the form
I authorize the above comments be posted on this page
Post Comment
Weekly Digest Opt-In

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

MORE TOP STORIES

In the first federal trial over claims of Uber driver sexual assaults, a lawsuit involving the rape of a passenger will go before a jury on January 13.
More than 2,000 Depo-Provera brain tumor lawsuits have been filed in state and federal courts nationwide, according to recent court documents, with potentially thousands more claims pending.
A federal judge will meet with lead counsel in the Suboxone litigation tomorrow to receive an update on the number of Suboxone lawsuits filed and the status of discovery.